Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Immunocytokines: A promising approach to cancer immunotherapy

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lode, H. N.
  • Xiang, R.
  • Becker, J. C.
  • Gillies, S. D.
  • Reisfeld, Ralph

publication date

  • December 1998

journal

  • Pharmacology & Therapeutics  Journal

abstract

  • Recombinant antibody-cytokine fusion proteins are immunocytokines that achieve high cytokine concentrations in the tumor microenvironment and thereby effectively stimulate cellular immune responses against malignancies. The activation and expansion of immune effector cells, such as CD8+ T lymphocytes, by interleukin-2 immunocytokines resulted in the eradication of established pulmonary and hepatic metastases of murine melanoma and colorectal carcinoma in syngeneic mouse models. These immunocytokines were equally effective in eliminating established bone marrow and liver metastases of murine neuroblastoma by activating natural killer cells. The effective eradication of metastases by immunocytokines resulted in significant prolongation in life span of mice over that of controls receiving equivalent mixtures of antibody and interleukin-2, which failed to reduce the growth of disseminated metastases. Proof of concept was established, indicating that immunocytokine-induced activation and expansion of immune effector cells in the tumor microenvironment can effectively eradicate established tumor metastases. This promising new approach to cancer immunotherapy may lead to clinical applications that improve treatment of cancer patients with minimal residual disease in an adjuvant setting.

subject areas

  • Animals
  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Cytokines
  • Disease Models, Animal
  • Humans
  • Immunotherapy
  • Melanoma
  • Mice
scroll to property group menus

Research

keywords

  • T-cells
  • immunocytokines
  • immunotherapy
  • interleukin-2
  • monoclonal antibodies
  • natural killer cells
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0163-7258

Digital Object Identifier (DOI)

  • 10.1016/s0163-7258(98)00033-3

PubMed ID

  • 9888698
scroll to property group menus

Additional Document Info

start page

  • 277

end page

  • 292

volume

  • 80

issue

  • 3

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support